Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration With Gates Institute At University Of Colorado Anschutz Medical Campus

6/25/24 8:11:19 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $CRL alert in real time by email

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers

Charles River Laboratories International, Inc. (NYSE:CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.

Get the next $CRL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRL

Date	Price Target	Rating	Analyst
11/18/2024	$164.00	Hold → Underperform	CLSA
11/7/2024	$205.00	Underperform → Hold	CLSA
10/23/2024	$167.00	Underperform	CLSA
10/14/2024		Sell	Redburn Atlantic
10/7/2024	$225.00 → $190.00	Outperform → In-line	Evercore ISI
10/2/2024	$250.00 → $215.00	Buy → Neutral	BofA Securities
10/1/2024	$215.00 → $175.00	Neutral → Sell	Citigroup
8/8/2024	$239.00 → $191.00	Outperform → Neutral	Robert W. Baird

More analyst ratings

$CRL
Press Releases

Fastest customizable press release news feed in the world

Charles River Laboratories to Present at UBS and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain availabl
11/11/24 8:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River Laboratories Announces Third-Quarter 2024 Results
– Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organ
11/6/24 7:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River Launches New Retrogenix® Non-Human Protein Library
First-in-class in vitro library assesses off-target binding to de-risk in vivo studies Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection. "Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro," said Aidan Synnott, Ph.D., Corporate Vice President, Global Discovery. "These early insights are generated withou
10/17/24 8:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care

$CRL
Financials

Live finance-specific insights

Charles River Laboratories Announces Third-Quarter 2024 Results
– Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organ
11/6/24 7:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
10/16/24 4:30:00 PM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River Laboratories Announces Second-Quarter 2024 Results
– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06 billion in the second quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.3%, a divestiture reduced reported revenue by 0.2%, and an acquisition contributed 0.5% to consolidated second-quarter revenue. Excluding the effect of t
8/7/24 7:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care

Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
7/24/24 8:00:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated
1/24/24 4:30:00 PM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology researchCharles River to make an equity investment in Aitia as part of the agreementWILMINGTON, Mass. and SOMERVILLE, Mass., Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
11/13/23 9:04:00 AM ET
$CRL
Biotechnology: Commercial Physical & Biological Resarch
Health Care

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration With Gates Institute At University Of Colorado Anschutz Medical Campus

Chat with this insight

Recent Analyst Ratings for $CRL

$CRL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Charles River downgraded by CLSA with a new price target

Charles River upgraded by CLSA with a new price target

CLSA initiated coverage on Charles River with a new price target

$CRL Press Releases

Fastest customizable press release news feed in the world

Charles River Laboratories to Present at UBS and Jefferies Conferences

Charles River Laboratories Announces Third-Quarter 2024 Results

Charles River Launches New Retrogenix® Non-Human Protein Library

$CRL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chairman, President and CEO Foster James C gifted 4,500 shares, decreasing direct ownership by 2% to 184,783 units (SEC Form 4)

Director Wallman Richard F gifted 4,540 shares and sold $1,647,418 worth of shares (7,621 units at $216.17), decreasing direct ownership by 47% to 12,386 units (SEC Form 4)

Corporate Executive VP & CCO Barbo William D gifted 470 shares (SEC Form 4)

$CRL SEC Filings

SEC Form 10-Q filed by Charles River Laboratories International Inc.

Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Charles River Laboratories International Inc.

$CRL Financials

Live finance-specific insights

Charles River Laboratories Announces Third-Quarter 2024 Results

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Charles River Laboratories Announces Second-Quarter 2024 Results

$CRL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

Foster James C bought $1,000,641 worth of shares (5,620 units at $178.05), increasing direct ownership by 3% to 202,643 units (SEC Form 4)

$CRL Leadership Updates

Live Leadership Updates

$CRL Market Insights

Live Market Insights

$CRL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Charles River And Autobahn Labs Establish Partnership To Accelerate Academic Discoveries Into Novel Therapeutics; Charles River To Make Equity Investment In Autobahn Labs; Chief Scientific Officer Justin Bryans Named To Autobahn's Board Of Directors

Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Baird Maintains Outperform on Charles River, Lowers Price Target to $239

SEC Form SC 13G filed by Charles River Laboratories International Inc.

Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

Recent Analyst Ratings for
$CRL

$CRL
Analyst Ratings

$CRL
Press Releases

$CRL
Insider Trading

$CRL
SEC Filings

$CRL
Financials

$CRL
Insider Purchases

$CRL
Leadership Updates

$CRL
Market Insights

$CRL
Large Ownership Changes